{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:16:18Z","timestamp":1778717778290,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":9,"publisher":"Springer US","isbn-type":[{"value":"9781071650400","type":"print"},{"value":"9781071650417","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5041-7_23","type":"book-chapter","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:58:04Z","timestamp":1778716684000},"page":"521-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-Drug Conjugates Synthesis Using Maleimide Chemistry"],"prefix":"10.1007","author":[{"given":"Camille","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenivasachary","family":"Nampally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"23_CR1","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.3390\/molecules26195847","volume":"26","author":"JTW Tong","year":"2021","unstructured":"Tong JTW, Harris PWR, Brimble MA, Kavianinia I (2021) An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules 26:5847. https:\/\/doi.org\/10.3390\/molecules26195847","journal-title":"Molecules"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","volume":"15","author":"H Maecker","year":"2023","unstructured":"Maecker H, Jonnalagadda V, Bhakta S et al (2023) Exploration of the antibody\u2013drug conjugate clinical landscape. MAbs 15:2229101. https:\/\/doi.org\/10.1080\/19420862.2023.2229101","journal-title":"MAbs"},{"key":"23_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z (2018) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0","journal-title":"Protein Cell"},{"key":"23_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631\u2013637. https:\/\/doi.org\/10.1038\/nbt.2289","journal-title":"Nat Biotechnol"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1021\/acs.molpharmaceut.6b00082","volume":"13","author":"G Brachet","year":"2016","unstructured":"Brachet G, Respaud R, Arnoult C et al (2016) Increment in drug loading on an antibody-drug conjugate increases its binding to the human neonatal Fc receptor in vitro. Mol Pharm 13:1405\u20131412. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00082","journal-title":"Mol Pharm"},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1021\/bc800289a","volume":"19","author":"SO Doronina","year":"2008","unstructured":"Doronina SO, Bovee TD, Meyer DW et al (2008) Novel peptide linkers for highly potent antibody\u2212auristatin conjugate. Bioconjug Chem 19:1960\u20133. https:\/\/doi.org\/10.1021\/bc800289a","journal-title":"Bioconjug Chem"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1021\/acs.bioconjchem.2c00015","volume":"33","author":"L Juen","year":"2022","unstructured":"Juen L, Baltus CB, G\u00e9ly C et al (2022) Therapeutic potential of MF-TTZ-MMAE, a site-specifically conjugated antibody-drug conjugate, for the treatment of HER2-overexpressing breast cancer. Bioconjug Chem 33:418\u2013426. https:\/\/doi.org\/10.1021\/acs.bioconjchem.2c00015","journal-title":"Bioconjug Chem"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jpba.2017.01.013","volume":"137","author":"S Fekete","year":"2017","unstructured":"Fekete S, Moln\u00e1r I, Guillarme D (2017) Separation of antibody drug conjugate species by RPLC: a generic method development approach. J Pharm Biomed Anal 137:60\u201369. https:\/\/doi.org\/10.1016\/j.jpba.2017.01.013","journal-title":"J Pharm Biomed Anal"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpba.2014.04.011","volume":"101","author":"S Fekete","year":"2014","unstructured":"Fekete S, Beck A, Veuthey J, Guillarme D (2014) Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J\u00a0Pharm Biomed Anal 101:161\u201373. https:\/\/doi.org\/10.1016\/j.jpba.2014.04.011","journal-title":"J Pharm Biomed Anal"}],"container-title":["Methods in Molecular Biology","Antibody Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5041-7_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:58:05Z","timestamp":1778716685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5041-7_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650400","9781071650417"],"references-count":9,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5041-7_23","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"14 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Camille Martin and Sreenivasachary Nampally are employees of AC Immune and are entitled to options and\/or shares. This study was funded by AC Immune SA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}